Susquehanna maintains RXO at Neutral, raises price target to $30 from $19

What happened

Susquehanna kept its Neutral rating on RXO and raised its price target to $30 from $19. The new target is 9.1% above RXO’s October 30 closing price of $27.49. The five most recent analyst targets over the past 30 days ranged from $30 to $30.25.

Confirmed

Global impact / market context

The higher target signals that Susquehanna sees more potential value in RXO than before, but its unchanged Neutral rating shows it did not shift to a clear Buy view. The target is an analyst estimate, not a promised share price or company result.

Analyst inference

Other recent analyst targets listed in the article cluster between $30 and $30.25, close to Susquehanna’s revised $30 estimate. This narrow range indicates similar near-term valuation views among these analysts, while their ratings include Buy, Neutral, Hold, and Equal-Weight.

Analyst inference

What to watch

1. Check whether later analyst updates change their ratings or targets; further revisions could shift investor expectations about RXO’s value and influence demand for its shares. Analyst inference
2. Compare RXO’s future reported business results with the assumptions behind the $30 target, since revenue and costs determine whether expectations are supported. Analyst inference
3. The article reports Susquehanna’s Neutral rating and $30 target, while the five latest analyst targets cited range from $30 to $30.25. Confirmed

Evidence

• Original source link unavailable